Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 10 | 2025 | 167 | 2.860 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 7 | 2022 | 7 | 1.700 |
Why?
|
| Auditory Perception | 5 | 2018 | 5 | 1.690 |
Why?
|
| Hearing Loss, Noise-Induced | 3 | 2022 | 3 | 1.560 |
Why?
|
| Homosexuality, Male | 5 | 2025 | 41 | 1.430 |
Why?
|
| Anura | 6 | 2021 | 12 | 1.340 |
Why?
|
| Male | 26 | 2025 | 2620 | 1.290 |
Why?
|
| Deafness | 4 | 2023 | 6 | 1.250 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 12 | 1.200 |
Why?
|
| Prisoners | 2 | 2025 | 13 | 1.190 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 62 | 1.120 |
Why?
|
| Pre-Exposure Prophylaxis | 5 | 2025 | 43 | 1.050 |
Why?
|
| Female | 19 | 2025 | 2964 | 1.030 |
Why?
|
| Auditory Threshold | 5 | 2022 | 5 | 0.990 |
Why?
|
| Hearing Loss | 3 | 2020 | 8 | 0.990 |
Why?
|
| Animals | 20 | 2023 | 1369 | 0.980 |
Why?
|
| Humans | 25 | 2025 | 4931 | 0.910 |
Why?
|
| Noise | 4 | 2022 | 4 | 0.860 |
Why?
|
| Sexual and Gender Minorities | 4 | 2024 | 20 | 0.820 |
Why?
|
| Diet | 5 | 2023 | 95 | 0.800 |
Why?
|
| Vocalization, Animal | 4 | 2017 | 4 | 0.750 |
Why?
|
| Young Adult | 8 | 2025 | 382 | 0.740 |
Why?
|
| Adult | 10 | 2025 | 1402 | 0.690 |
Why?
|
| Sex Factors | 3 | 2017 | 120 | 0.670 |
Why?
|
| Physician Assistants | 3 | 2024 | 11 | 0.640 |
Why?
|
| Hyperkinesis | 1 | 2018 | 1 | 0.600 |
Why?
|
| Cochlear Nucleus | 1 | 2018 | 1 | 0.600 |
Why?
|
| Spiral Ganglion | 1 | 2018 | 2 | 0.600 |
Why?
|
| Behavior, Animal | 1 | 2018 | 28 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 258 | 0.580 |
Why?
|
| Middle Aged | 10 | 2025 | 1544 | 0.570 |
Why?
|
| Bias | 1 | 2017 | 5 | 0.560 |
Why?
|
| Biomedical Research | 1 | 2017 | 17 | 0.550 |
Why?
|
| Hearing | 5 | 2023 | 5 | 0.500 |
Why?
|
| Mice | 7 | 2023 | 555 | 0.500 |
Why?
|
| Mice, Inbred CBA | 5 | 2022 | 5 | 0.490 |
Why?
|
| Peripheral Nervous System | 1 | 2015 | 2 | 0.470 |
Why?
|
| Acoustic Stimulation | 6 | 2022 | 6 | 0.470 |
Why?
|
| Siblings | 2 | 2024 | 6 | 0.440 |
Why?
|
| Body Size | 1 | 2014 | 7 | 0.440 |
Why?
|
| Anti-HIV Agents | 3 | 2024 | 45 | 0.420 |
Why?
|
| Hair Cells, Auditory | 3 | 2020 | 3 | 0.360 |
Why?
|
| Los Angeles | 4 | 2025 | 244 | 0.320 |
Why?
|
| United States | 6 | 2024 | 764 | 0.320 |
Why?
|
| Pandemics | 3 | 2023 | 65 | 0.300 |
Why?
|
| Leadership | 3 | 2023 | 18 | 0.300 |
Why?
|
| Sexual Behavior | 3 | 2025 | 49 | 0.290 |
Why?
|
| Peer Group | 2 | 2025 | 12 | 0.280 |
Why?
|
| Neurons | 3 | 2017 | 41 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 93 | 0.270 |
Why?
|
| Aging | 3 | 2022 | 92 | 0.250 |
Why?
|
| Transgender Persons | 1 | 2025 | 12 | 0.240 |
Why?
|
| Sexual Partners | 2 | 2022 | 23 | 0.240 |
Why?
|
| Social Support | 1 | 2025 | 29 | 0.240 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 149 | 0.230 |
Why?
|
| Motivational Interviewing | 1 | 2024 | 4 | 0.230 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 47 | 0.230 |
Why?
|
| Cochlea | 2 | 2022 | 3 | 0.220 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 50 | 0.220 |
Why?
|
| Vestibular Diseases | 1 | 2023 | 1 | 0.220 |
Why?
|
| CHARGE Syndrome | 1 | 2023 | 1 | 0.220 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 3 | 0.220 |
Why?
|
| Abnormalities, Multiple | 1 | 2023 | 4 | 0.220 |
Why?
|
| Face | 1 | 2023 | 3 | 0.220 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 4 | 0.220 |
Why?
|
| Food | 1 | 2023 | 6 | 0.220 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 358 | 0.210 |
Why?
|
| Physicians | 1 | 2023 | 37 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 10 | 0.210 |
Why?
|
| Mentoring | 1 | 2023 | 12 | 0.200 |
Why?
|
| Exercise | 1 | 2023 | 41 | 0.200 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 26 | 0.200 |
Why?
|
| Education, Medical | 1 | 2022 | 18 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 11 | 0.200 |
Why?
|
| Minority Groups | 1 | 2022 | 53 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 5 | 0.190 |
Why?
|
| Sex Characteristics | 2 | 2020 | 24 | 0.190 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 8 | 0.190 |
Why?
|
| Reflex, Startle | 1 | 2022 | 1 | 0.190 |
Why?
|
| Chiroptera | 1 | 2021 | 1 | 0.190 |
Why?
|
| Echolocation | 1 | 2021 | 1 | 0.190 |
Why?
|
| Mexican Americans | 1 | 2021 | 12 | 0.180 |
Why?
|
| Psychoacoustics | 3 | 2020 | 3 | 0.180 |
Why?
|
| Aged | 3 | 2023 | 1188 | 0.180 |
Why?
|
| Animal Communication | 1 | 2021 | 1 | 0.180 |
Why?
|
| Curcumin | 1 | 2020 | 5 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 9 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 49 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2021 | 52 | 0.170 |
Why?
|
| Mole Rats | 1 | 2020 | 1 | 0.170 |
Why?
|
| Species Specificity | 3 | 2015 | 14 | 0.170 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 3 | 0.170 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 2 | 0.170 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 8 | 0.170 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 1 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 15 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2021 | 69 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 51 | 0.170 |
Why?
|
| Visual Cortex | 1 | 2018 | 1 | 0.150 |
Why?
|
| Visual Perception | 1 | 2018 | 1 | 0.150 |
Why?
|
| Long-Term Potentiation | 1 | 2018 | 1 | 0.150 |
Why?
|
| Thalamus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Sexism | 1 | 2018 | 4 | 0.150 |
Why?
|
| Inferior Colliculi | 1 | 2017 | 1 | 0.140 |
Why?
|
| Rana clamitans | 1 | 2017 | 1 | 0.140 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 2 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 179 | 0.140 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2017 | 2 | 0.140 |
Why?
|
| Catecholamines | 1 | 2017 | 5 | 0.140 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 4 | 0.140 |
Why?
|
| Reaction Time | 2 | 2014 | 12 | 0.140 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 4 | 0.110 |
Why?
|
| Models, Biological | 1 | 2014 | 46 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2024 | 21 | 0.110 |
Why?
|
| Sound Localization | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tympanic Membrane | 1 | 2014 | 3 | 0.110 |
Why?
|
| Electrophysiology | 1 | 2014 | 7 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2014 | 53 | 0.110 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 1 | 0.110 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 7 | 0.110 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 9 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 41 | 0.100 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2013 | 5 | 0.100 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 18 | 0.100 |
Why?
|
| Educational Status | 2 | 2023 | 45 | 0.100 |
Why?
|
| Child | 2 | 2023 | 336 | 0.090 |
Why?
|
| Research Design | 2 | 2023 | 32 | 0.090 |
Why?
|
| Adolescent | 2 | 2022 | 569 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 12 | 0.080 |
Why?
|
| Lung | 2 | 2021 | 41 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2024 | 53 | 0.060 |
Why?
|
| Motivation | 1 | 2024 | 31 | 0.060 |
Why?
|
| Causality | 1 | 2023 | 7 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 224 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 11 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 12 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 8 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 5 | 0.050 |
Why?
|
| Eating | 1 | 2023 | 28 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2023 | 135 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2022 | 4 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2022 | 16 | 0.050 |
Why?
|
| Viral Load | 1 | 2022 | 11 | 0.050 |
Why?
|
| Depression | 1 | 2023 | 97 | 0.050 |
Why?
|
| Incidence | 1 | 2022 | 141 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 59 | 0.050 |
Why?
|
| Benzeneacetamides | 2 | 2013 | 2 | 0.050 |
Why?
|
| Pyrrolidines | 2 | 2013 | 4 | 0.050 |
Why?
|
| Fentanyl | 2 | 2013 | 7 | 0.050 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sirolimus | 1 | 2020 | 5 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 35 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 13 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 21 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 28 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 19 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 2 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 3 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2020 | 2 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 184 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 7 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2020 | 9 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 104 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 137 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 62 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2020 | 35 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 101 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 162 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 593 | 0.040 |
Why?
|
| Interneurons | 1 | 2018 | 1 | 0.040 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2018 | 2 | 0.040 |
Why?
|
| Sensory Deprivation | 1 | 2018 | 2 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 5 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 16 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 196 | 0.040 |
Why?
|
| Auditory Pathways | 1 | 2017 | 1 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2017 | 1 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2017 | 2 | 0.040 |
Why?
|
| Action Potentials | 1 | 2017 | 4 | 0.040 |
Why?
|
| Methylation | 1 | 2017 | 7 | 0.030 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2014 | 1 | 0.030 |
Why?
|
| Tubocurarine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 3 | 0.030 |
Why?
|
| Immobilization | 1 | 2014 | 4 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 4 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 27 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 83 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vibration | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 3 | 0.030 |
Why?
|
| Motor Activity | 1 | 2014 | 24 | 0.030 |
Why?
|
| Wakefulness | 1 | 2013 | 5 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 13 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 2013 | 3 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 16 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2013 | 23 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2013 | 12 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2013 | 30 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2013 | 41 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 2 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 8 | 0.020 |
Why?
|
| Self Administration | 1 | 2008 | 6 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2008 | 8 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 45 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2008 | 16 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 26 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 126 | 0.020 |
Why?
|